CTHRC1 and PD ‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer.

CTHRC1 and PD‑1/PD‑L1 expression predicts tumor recurrence in prostate cancer. Mol Med Rep. 2019 Sep 19;: Authors: Zhou Q, Xiong W, Zhou X, Gao RS, Lin QF, Liu HY, Li JN, Tian XF Abstract Collagen triple helix repeat containing 1 (CTHRC1) is a gene that has been associated with tumor progression in human prostate cancer (PC). The tumor immune microenvironment has been linked with disease outcome in PC. In the present study, the correlation between CTHRC1 with PC recurrence and the tumor immunological microenvironment was investigated. Using the data supplied by the Tumor Immune Estimation Resource (TIMER), the expression of CTHRC1, programmed cell death protein 1 (PD‑1), and programmed cell death 1 ligand 1 (PD‑L1) were analyzed. Immunohistochemical staining of CTHRC1, PD‑1 and PD‑L1 was performed using a tissue microarray construction of prostate adenocarcinoma (PRAD) specimens. In PRAD, an association was reported between the CTHRC1 expression and the disease free survival (DFS) rate (P=0.022). Overexpression of CTHRC1 was correlated with increased levels of PD‑1 (R=0.272, P=0.021) and PD‑L1 (R=0.298, P=0.016), elevated levels of infiltrating B cells (P=9.51e‑11), CD4+ cells (P=1.51e‑11), macrophages (P=8.25e‑5), neutrophils (P=2.17e‑9) and dendritic cells (P=3.13e‑13). Bioinformatics analysis revealed that CTHRC1 was correlated with the expression levels of matrix metalloproteinase‑9, mucin 1 and solute carrier organic anion...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Related Links:

CONCLUSIONS: Incidental prostate cancer had a higher prevalence than previously expected in our cohort (24.4%), but it had no impact in overall survival of patients not even in those with a significant prostate cancer. No biochemical recurrence was reported during the study. PMID: 31697251 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
We presented a promising result of radionuclide therapy using Lu-PSMA and Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. PMID: 31689280 [PubMed - in process]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Nucl Med Source Type: research
In this study, we employ an optimized, high signal-to-noise ratio hyperpolarized (HP) 13C pHe imaging method to discriminate between indolent and aggressive disease in a murine model of prostate cancer. Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice underwent a multiparametric MR imaging exam, including HP [13C] bicarbonate MRI for pHe, with 1H apparent diffusion coefficient (ADC) mapping and HP [1-13C] pyruvate MRI to study lactate metabolism. Tumor tissue was excised for histological staining and qRT-PCR to quantify mRNA expression for relevant glycolytic enzymes and transporters. We observed good separatio...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In conclusion, the PJE treatment promoted protective effects in the metabolism of insulin and glucose and liver imbalance caused by HFD intake in the PCa model, suggesting that it may be a good protector against metabolic disorders present in overweight and associated with PCa. PMID: 31696743 [PubMed - as supplied by publisher]
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
Gold nanospheres can be functionalized with interleukin ‐12 (IL12), a potent anticancer and immunostimulatory cytokine, and a cyclic peptide containing the isoDGR motif (Iso1) that, after coupling to albumin (Iso1‐HSA), recognizes the αvβ3 integrin overexpressed in tumor vessels and on different tumor cell types. Bifunctional nanospheres (Iso1/Au/I L12) increase the infiltration of immune cells and inhibit tumor growth in preclinical tumor models. AbstractThe clinical use of interleukin ‐12 (IL12), a cytokine endowed with potent immunotherapeutic anticancer activity, is limited by systemic toxicity. The hy...
Source: Small - Category: Nanotechnology Authors: Tags: Full Paper Source Type: research
We describe herein the results of the first HMGB1/HMGB2 interactome approach to PCa. Libraries constructed from the PCa cell line, PC-3, and from patients’ PCa primary tumor have been screened by the yeast 2-hybrid approach (Y2H) using HMGB1 and HMGB2 baits. Functional significance of this PCa HMGB interactome has been validated through expression and prognosis data available on public databases. Copy number alterations (CNA) affecting these newly described HMGB interactome components are more frequent in the most aggressive forms of PCa: those of neuroendocrine origin or castration-resistant PCa. Concordantly, a...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Conditions:   Prostate Cancer;   Prostate Adenocarcinoma Intervention:   Sponsors:   I.M. Sechenov First Moscow State Medical University;   Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy;   Pirogov Russian National Research Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Biochemically Recurrent Prostate Carcinoma;   Prostate Adenocarcinoma;   PSA Failure;   PSA Progression Interventions:   Combination Product: Carbon C 11 Choline;   Procedure: Computed Tomography;   Other: Gallium Ga 68-labeled PSMA-11;   Procedure: Positron Emission Tomography Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Allergy & Immunology | Cancer | Cancer & Oncology | Genetics | Molecular Biology | Organic | Prostate Cancer | Study